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Abstract. Primary effusion lymphoma (PEL) is a B‑cell 
non‑Hodgkin's lymphoma that is usually characterized by 
lymphomatous effusions in the body cavity without any 
detectable tumor masses. According to the World Health 
Organization (WHO) schema for tumor classification, 
PEL is defined by the presence of human herpesvirus 8 
(HHV8) in malignant lymphoid cells. However, a subset 
of effusion‑based B‑cell lymphoma is not HHV8‑positive 
and exhibits different clinicopathological characteristics. 
The 2017 WHO Classification of Tumors of Hematopoietic 
and Lymphoid Tissues does not list HHV8‑negative effu‑
sion‑based lymphoma, which remains an underappreciated 
B‑cell lymphoma, as an individual entity. The present 
study reports a case of this rare type of lymphoma with 
indolent clinical behavior in a 75‑year‑old male patient 
receiving only symptomatic treatment. Additionally, a 
review of similar cases reported in the English literature 
is presented.
Introduction
Primary effusion lymphoma (PEL) is a rare and distinct 
type of non‑Hodgkin's lymphoma typically characterized by 
serous effusions without any detectable tumor masses (1). 
It accounts for ~4% of all human immunodeficiency virus 
(HIV)‑related non‑Hodgkin lymphoma (NHL) cases and 
<1% of all non‑HIV‑related NHL cases in the United States 
(between 2001 and 2012) (1). According to the 2017 World 
Health Organization (WHO) Classification of Tumors of 
Hematopoietic and Lymphoid Tissues (2), human herpes‑
virus 8 (HHV8) infection is commonly detected in neoplastic 
lymphoid cells. Most cases of PEL are associated with an 
immunocompromised status, particularly human immuno‑
deficiency virus (HIV) infection, and frequently, there is 
co‑infection with Epstein‑Barr virus (EBV) (3). Neoplastic 
tumor cells exhibit a wide range of cytological appearances, 
from immunoblastic to anaplastic morphology (3). Although 
HHV8‑negative effusion‑based lymphoma, a rare and 
underappreciated subgroup of non‑Hodgkin's lymphoma, is 
cytomorphologically similar to PEL, it exhibits several distinct 
clinicopathological characteristics since it generally develops 
in older patients with better outcomes; unlike PEL, the 
neoplastic cells in HHV8‑negative effusion‑based lymphoma 
express pan‑B‑cell markers (4).
In the present report, a 75‑year‑old male with an indo‑
lent variant of HHV8‑negative effusion‑based lymphoma is 
described. In addition, a brief review of similar cases reported 
in the literature is presented.
Case report
A 75‑year‑old male patient presented with cough and shortness 
of breath, which lasted for 1 month. The patient was admitted 
to Severance Hospital (Seoul, South Korea) in December 2018. 
Written informed consent for participation in the present study 
was obtained from the patient. The patient had a medical 
history of hypertension and tuberculosis, which was treated 
with anti‑tuberculous drugs 50 years ago. The patient was a 
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former smoker (1 pack/day for 10 years) but stopped smoking 
45 years ago. Chest X‑ray revealed cardiomegaly and mild 
pleural effusion. Electrocardiogram revealed atrial fibril‑
lation with a right bundle branch block. A complete blood 
count provided results within the normal ranges [white blood 
cell (WBC), 6,540/µl (normal range, 4,000‑10,800/µl); red 
blood cell (RBC), 5.01x106/µl (normal range, 4.4‑6.1x106/µl); 
hemoglobin, 15.4 g/dl (normal range, 13.0‑17.4 g/dl); hemato‑
crit, 46.1% (normal range, 40‑52%)]. The amounts of lactate 
hydrogenase and total protein in the blood serum were 205 IU/l 
(normal, 119‑247 IU/l) and 7.0 g/dl (normal, 6.0‑8.0 g/dl), 
respectively. Immunoassays for the detection of HIV antibody, 
hepatitis B surface antigen and hepatitis C virus (HCV) antigen 
were performed following routine hospital procedures and 
the results were all negative (data not shown). Transthoracic 
echocardiogram (TTE) revealed enlarged left and right atria, 
mild pulmonary hypertension (right ventricular systolic 
pressure, 43 mmHg) with dilated inferior vena cava, and a 
moderate amount of pericardial effusion. The patient refused 
hospital admission for a further diagnostic work‑up. Diuretics 
were administered to control the pericardial effusion. After 
6 months, the patient presented with aggravated dyspnea and a 
continuous low‑grade fever. Chest computed tomography (CT) 
demonstrated pleural thickening and effusion (Fig. 1A), but 
neither hilar lymphadenopathy nor a mass lesion was detected. 
A positron emission‑CT (PET‑CT) scan showed mildly 
increased 18F‑fluorodeoxyglucose uptake in the left pleura 
(Fig. 1B). A follow‑up TTE revealed constrictive pericarditis, 
as well as persistent left atrial enlargement and pleural effusion. 
A thoracentesis was performed under a tentative diagnosis of 
tuberculous pericarditis and pleurisy. Pleural fluid analysis 
revealed the following counts: RBC, 30,000/µl (normal range, 
0‑100,000/µl); WBC, 10,446/µl (normal range, 0‑10,000/µl); 
protein, 4,800 mg/dl (normal range, 0‑2000 mg/dl); glucose, 
16 mg/dl (normal range, 0‑60 mg/dl); lactate dehydrogenase, 
4,355 IU/l (normal range, 100‑300 IU/l); and adenosine deami‑
nase, 698.4 IU/l (normal range, 0‑40 IU/l). Microbiological 
tests for tuberculosis, including an acid‑fast bacilli smear, 
quantitative polymerase chain reaction and cultures, were 
performed according to routine procedures, and the results 
were all negative (data not shown).
Morphological analysis of the pleural fluid revealed the 
presence of numerous apoptotic figures and large atypical 
cells with cytomorphological features of centroblasts in the 
pleural fluid (Fig. 2A).
For immunohistochemistry, the cytology cell block from 
the pleural fluid aspiration was fixed with 10% buffered neutral 
formalin at room temperature overnight and embedded in 
paraffin. Tissue sections (4‑µm‑thick) from paraffin‑embedded 
cell blocks were deparaffinized and rehydrated with 
xylene and a descending alcohol series. Immunostaining 
was performed using automatic immunostaining instru‑
ments, namely Ventana Benchmark XT automated staining 
system (Ventana Medical Systems) or Dako Omnis (Dako; 
Agilent Technologies, Inc.), according to the manufacturer's 
recommendations. Antigen retrieval was performed using 
Cell Conditioning Solution (Ventana Medical Systems) or 
EnVision FLEX Target Retrieval Solution, High pH (Dako; 
Agilent Technologies, Inc.). Endogenous peroxidase activity 
was blocked using 3% hydrogen peroxide at room temperature 
for 15 min. The sections were then incubated with primary anti‑
bodies at 37˚C for 32 min against CD45 (mouse monoclonal; 
clone 2B11; 1:50; cat. no. M0701; Agilent Technologies, Inc.), 
CD20 (mouse monoclonal; clone L26; 1:50; cat. no. M0755; 
Dako; Agilent Technologies, Inc.), CD79a (mouse mono‑
clonal; clone JCB117; 1:50; cat. no. M7050; Dako; Agilent 
Technologies, Inc.), paired box 5 (PAX5; rabbit monoclonal; 
clone SP34; 1:100; cat. no. 790‑4420; Ventana Medical 
Systems, Inc.), CD138 (mouse monoclonal; clone MI15; 1:100; 
cat. no. M7228; Dako; Agilent Technologies, Inc.), MYC 
(rabbit monoclonal; clone EP121; 1:50; cat. no. 395R‑15; Cell 
Marque; Merck KGaA), BCL‑2 (mouse monoclonal; clone 
124; 1:100; cat. no. M0887; Dako; Agilent Technologies, 
Inc.), BCL‑6 (mouse monoclonal; clone G1191E/A8; 1:100; 
cat. no. 227M‑96; Cell Marque; Merck KGaA), CD3 (rabbit 
polyclonal; 1:100; cat. no. A0452; Dako; Agilent Technologies, 
Inc.), CD68 (mouse monoclonal; clone PG‑M1; 1:200; 
cat. no. M0876; Dako; Agilent Technologies, Inc.), calretinin 
(mouse monoclonal; clone DAK‑Calret 1; 1:50; cat. no. M7245; 
Dako; Agilent Technologies, Inc.), Ki‑67 (mouse monoclonal; 
clone MB‑1; 1:150; cat. no. M7240; Agilent Technologies, 
Inc.) and HHV8 (mouse monoclonal; clone 13B10; 1:100; 
cat. no. 760‑4260; Ventana Medical Systems, Inc.). After 
chromogenic visualization using an ultraView Universal DAB 
Detection kit (Ventana Medical Systems; cat. no. 760‑500, 
including secondary antibody incubation at 37˚C for 8 min 
using ultraView Universal HRP Multimer), sections were 
counterstained with hematoxylin at 37˚C for 8 min. Light 
microscopy (BX43 System Microscope; Olympus Corporation; 
magnification, x40‑400) was used to observe the sections. 
Appropriate positive controls were stained concurrently to 
validate the staining method. Negative controls were prepared 
by substituting non‑immune serum (mouse monoclonal IgG κ 
isotype control; clone P3.6.2.8.1; cat. no. AB_1944423; 
Invitrogen; Thermo Fisher Scientific, Inc.) for the primary 
antibody. No staining was detected in the negative controls.
Immunohistochemistry analysis revealed that the atypical 
cells were uniformly positive for CD45 and that a subset of 
these cells exhibited varying degrees of CD20 expression 
(Fig. 2B), CD79a and PAX5. The cells were negative for CD138 
(Fig. 2C). Although 10% of the atypical cells were positive for 
focal MYC (Fig. 2D), they were negative for BCL‑2 (Fig. 2E), 
BCL‑6 (Fig. 2F), CD3, CD68 and calretinin. The Ki‑67 
labeling index was 73.5%, accounting for the average of four 
high‑power fields (Fig. 2G). The atypical cells were negative 
for HHV8 (Fig. 2H), and EBV‑encoded RNA was not detected 
in the nuclei of the atypical cells (Fig. 2I) using in situ hybrid‑
ization, which was performed as previously described (5). 
Pathological features in the patient suggested the possibility of 
an unusual variant of PEL or diffuse large B‑cell lymphoma 
associated with chronic inflammation. As the patient's symp‑
toms remained stable, symptomatic treatment was provided 
and the patient was closely followed up. The mild pleural 
effusion persisted over a 1‑year follow‑up period. Repeated 
pleural fluid analysis revealed large atypical cells with the 
same cytological features of centroblasts and immunopheno‑
typic features. Some large atypical cells expressed MUM1, 
but were negative for HHV8, CD30 and CD138. Polymerase 
chain reaction analysis of immunoglobulin heavy chain 
(IgH) gene rearrangement was performed using BIOMED‑2 
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multiplex primers in accordance with the manufacturer's 
protocol (Invivoscribe, Inc.) as previously described (6). The 
reaction assays for the IgH rearrangement tests involved a 
full set of five reactions targeting the IGH (IGHA, FR1‑JH; 
IGHB, FR2‑JH; IGHC, FR3‑JH; IGHD, DH1‑6‑JH; and 
IGHE, DH7‑JH). The results demonstrated clonal rearrange‑
ment of the IgH gene (Fig. 3). The pathological diagnosis of 
HHV8‑negative effusion‑based lymphoma was made on the 
basis of clinicopathological findings noted 6 months after the 
first visit of the patient. The pleural effusion resolved following 
the insertion of a drainage catheter. Systemic imaging including 
a PET‑CT scan demonstrated no other lesions. Thus, the 
patient was closely observed without chemotherapy. Follow‑up 
chest CT, which was performed at 10 months post‑diagnosis, 
Figure 2. Histopathological and immunohistochemical findings in HHV8‑negative effusion‑based lymphoma. (A) Cytomorphological appearance of malignant 
lymphoid cells in the pleural fluid (magnification, x1,000). Malignant cells showing (B) membranous CD20 staining (magnification, x100) and (C) no staining 
for CD138 (magnification, x40). Tumor cells showing (D) focal positivity (10% of tumor cells) for c‑MYC (magnification, x200) and no staining for (E) BCL‑2 
(magnification, x200) and (F) BCL‑6 (magnification, x200). (G) Immunohistochemical staining for Ki‑67 revealed a labeling index of 73.5% (magnification, 
x100). (H) Immunohistochemical staining for HHV8 (magnification, x400) and (I) Epstein‑Barr virus‑encoded RNA in situ hybridization (magnification, 
x400) of the pleural fluid was negative. HHV8, human herpesvirus 8.
Figure 1. Chest CT and PET‑CT scans of the patient. (A) Chest CT revealing left pleural thickening and effusion. (B) PET‑CT scan showing mildly increased 
18F‑fluorodeoxyglucoseuptake uptake in the left pleura. CT, computed tomography; PET‑CT, positron emission tomography‑CT.
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did not reveal an increase in pleural effusion or suspicious 
pleural enhancement. At a regular 2‑month follow‑up for 
six visits in total, the patient was alive without any symptoms 
for 13 months post‑diagnosis.
Discussion
The present study reports a case of HHV8‑ and EBV‑negative 
pleural effusion‑based lymphoma with indolent clinical 
behavior in an elderly patient. Typical PEL occurs in 
immune‑compromised patients, particularly in those with 
HIV infection (7). HHV8 universally infects malignant 
lymphoid cells and encodes proteins that are essential for the 
proliferation and survival of tumor cells (8). Although EBV 
co‑infection is found in most cases of HHV8 infection, it is not 
considered to play an important role in the pathogenesis (9). 
The etiology of HHV8‑negative effusion‑based lymphoma 
is still unclear. EBV infection is seen in 28.9% of patients 
with HHV8‑negative effusion‑based lymphoma and 65.6% of 
patients with PEL (10). Paner et al (11) suggested a possible 
association between HHV8‑negative effusion‑based lymphoma 
and HCV; however, a subsequent study demonstrated HCV 
infection in only 10% of patients with HHV8‑negative 
effusion‑based lymphoma (3). Ohshima et al (12) proposed 
that the genetic alteration of MYC may be involved in the 
pathogenesis of HHV8‑negative effusion‑based lymphoma, 
and Ichinohasama et al (13) suggested that PAX5 aberration 
may play a role in the lymphomagenesis of HHV8‑negative 
effusion‑based lymphoma. Effusion or chronic serositis itself 
could create ideal body conditions for lymphomagenesis, 
similar to fibrin‑associated diffuse large B‑cell lymphoma 
and diffuse large B‑cell lymphoma associated with chronic 
inflammation (10). A large proportion of HHV8‑negative effu‑
sion‑based lymphoma is associated with fluid overload caused 
by different oedematous disorders, such as liver cirrhosis or 
heart failure. A study of 55 HHV8‑negative effusion‑based 
lymphoma cases reported cirrhosis and heart disease in 
10 (18.2%) and 9 (16.4%) cases, respectively (3). The present 
case was also associated with localized fluid overload caused 
by heart disease and tuberculous pleurisy that occurred several 
years previously.
As was observed in the present case, HHV8‑negative 
effusion‑based lymphoma typically occurs in elderly patients 
with a median age of 70 years (10). Studies consistently 
report a higher incidence of HHV8‑negative effusion‑based 
lymphoma in males compared with that in females (3,10). In 
a previous study, the median age of patients at presentation 
with PEL was 42 years in an HIV‑infected group, compared 
with 73 years in an immune‑competent group (2). The 
immunocompromised state is likely to be associated with 
the earlier onset of PEL as there is no substantial differ‑
ence in median age between patients with HHV8‑positive 
and HIV‑negative PEL and HHV8‑negative effusion‑based 
lymphoma.
Tumor cells in HHV8‑negative effusion‑based lymphoma 
exhibit cytological features ranging from immunoblasts to 
highly pleomorphic cells, which sometimes resemble Hodgkin 
cells commonly found in PEL (14). However, the tumor cells 
in HHV8‑negative effusion‑based lymphoma more commonly 
demonstrate either centroblast‑like or Burkitt‑like cytomor‑
phology compared with those in PEL (3,14). In the present case, 
most tumor cells exhibited the cytomorphological features of 
centroblasts.
Unlike in PEL, in which the tumor cells usually lack pan 
B‑cell markers, the majority of tumor cells in HHV8‑negative 
effusion‑based indolent lymphoma express pan B‑cell 
markers and do not express an activation marker or plasma 
cell‑associated antigen (15). The tumor cells in the present 
case also expressed pan B‑cell markers, although not all cells 
demonstrated uniform and strong expression of pan B‑cell 
marker; no tumor cells expressed activation markers or plasma 
cell‑associated antigens except MUM1.
Regarding genetics, HHV8‑negative effusion‑based 
lymphoma demonstrates complex genomic aberrations (12). 
Although cytogenetic analysis could not be performed in the 
present study, Ohshima et al (12) reported gain in 19 out of 24 
chromosomes in a comparative genomic hybridization study. 
They also reported complex chromosomal abnormalities 
in both number and structure, including t(8;22) or +8 chro‑
mosome and c‑myc amplification. Terasaki et al (16) also 
reported cases of HHV8‑negative effusion‑based lymphoma 
with complex karyotype abnormalities in a G‑band study.
HHV8‑negative effusion‑based lymphoma exhibits a 
less aggressive clinical course compared with PEL (17). 
Zaimoku et al (17) reported a markedly higher survival rate 
in patients with HHV8‑negative effusion‑based lymphoma 
(1‑year survival rate, 60.1%) compared with those with 
PEL (1‑year survival rate, 39.3%). Notably, the present case 
demonstrated no progression of disease over 1 year without 
chemotherapy. To the best of our knowledge, 12 patients 
Figure 3. Immunoglobulin heavy chain gene rearrangement test results for HHV8‑negative effusion‑based lymphoma. Detection of the clonal rearrangement 
of immunoglobulin heavy chain gene was consistent with the presence of a clonal B‑cell population based on the polymerase chain reaction‑based analysis of 
the immunoglobulin heavy chain gene rearrangement. Tube A, B and C contain the framework regions FR1‑JH, FR2‑JH and FR3‑JH, respectively. Tube D and 
E contain the diversity and joining regions (DH1‑6‑JH and DH7‑JH). M, size marker; P, positive control; N, negative control; S, sample (patient).
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with indolent HHV8‑negative effusion‑based lymphoma 
who survived longer than 1 year without treatment have been 
previously described, as identified by searching Pubmed 
(https://pubmed.ncbi.nlm.nih.gov/) using the key words 
‘HHV‑8’, ‘non‑Hodgkin lymphoma’, ‘effusion’, ‘immune 
compromised’ and ‘primary effusion lymphoma’ (7,15,18‑24) 
(Table I). Among the 13 cases (including the present case), there 
were 7 males and 6 females, with an age range of 60‑99 years 
(mean age, 80.1 years). The cases were either determined to 
be negative for HIV infection, hepatitis B virus infection and 
HCV infection, or the data were unavailable. Heart disease, 
including coronary artery disease and arrythmia, and chronic 
heart failure, were observed in 8 (61.6%) and 2 (15.4%) patients, 
respectively. EBV co‑infection in lymphoma cells was detected 
in 2 cases (15.4%). c‑MYC amplification was observed in 
1 case (7.7%). Cytomorphologically, centroblast‑like or small‑ 
to medium‑sized Burkitt‑like malignant lymphoid cells were 
observed more frequently in the cases summarized in Table I 
(3/13; 23.1%) than in a previous study on HHV8‑negative 
effusion‑based lymphoma (5/55; 9%) (3). Taken together, 
HHV8‑negative effusion‑based lymphoma with an indolent 
clinical course tends to occur in older patients with fewer 
comorbidities, a lower rate of related virus infections (such 
as HCV) and fewer aggressive cytomorphological features 
compared with conventional HHV8‑negative effusion‑based 
lymphoma. This suggests that HHV8‑negative effusion‑based 
lymphoma can be categorized into subgroups according to 
prognostic factors.
In summary, the present study reports a case of 
HHV8‑negative effusion‑based lymphoma with unusual 
indolent clinical behavior and presents a review of the char‑
acteristics of 13 biologically similar cases reported in the 
literature. The results suggest the existence of an indolent 
variant of HHV8‑negative effusion‑based lymphoma. In 
order to predict indolent clinical behavior in this rare type 
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